TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Total transfused red blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h ambulatory systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24-h ambulatory diastolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24-h ambulatory heart rate (HR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Levels of ECP in nasal lavage fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of MCT in nasal lavage fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of mature follicular cycles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Vertical jump performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiological volume stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft homogeneity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant stability quotient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in H accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum growth hormone immunoreactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: serum growth hormone bioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: serum BGH response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Absolute bioavailability of oxycodone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IGF‐1 level in the CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total amount of intraoperative fentanyl and propofol required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interobserver agreement for MR angiography vs MDCT angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary GAG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ability to walk
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: median percentage of days with diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: prevalence of upper respiratory symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: improvement in rhinitis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nasal index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance of eGFR estimates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: composite of fatal and non-fatal cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: primary patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: in-stent binary restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative target lesion reinterventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: serum concentration of sFas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Histologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRD levels in ficolled BMs compared to BM buffy coats
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of sepsis
Endpoint domain: Adverse events/effects
Primary endpoint: Brainstem-evoked response audiometry results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: DNA fragmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apoptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median percentage reduction in voiding frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Median percentage increase in volume voided per void
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in bladder symptoms relative to baseline
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction of color fading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tooth sensitivity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Per-protocol cure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS and ODI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-day fecal output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: WGTT (Whole Gut Transit Time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total bacteria count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Exercise capacity (Wmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle strength (leg press, bench press, bench pull)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of gadolinium-enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: progressive disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: True recognition rates (hit rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response bias (measured by C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton depression scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician-rated global improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient-rated global improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: total health service costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area of hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life (role physical scores)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Cosmetic scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mRNA expression of FOXO3A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mRNA expression of Atrogin-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mRNA expression of MuRF-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exceeding Hb ceiling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: use of analgesics
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: postoperative haemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long-term retention of laryngeal anatomy knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduced varus angulation of the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: daily total nasal symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rhinoconjunctivitis Quality of Life Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall Survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of postherpetic neuralgia (PHN)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to full opening of the affected eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal stain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Incidence of hepatic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Probability of remission
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in sleep (HAMD sleep subscale)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Postpartum smoking relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tPA antigen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Concordance with ADA process-of-care indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Screening rates for breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Screening rates for cervical cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Knowledge of epilepsy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Perception of epilepsy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Advanced therapy referral rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Bradykinesia severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Dyskinesia severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Mean arterial BP (MAP) response to acute RE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate Pressure Product (RPP) response to acute RE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of questions reported
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: blood glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Scores on the functional checklist of the UHDRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal static torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of weight-based dosage error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of wrong vial error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gadolinium-enhancing T1 lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: New/newly enlarging T2 lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Irisin levels post-exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rates of leucopenia and thrombocytopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Binge frequency improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binge abstinence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of infarct detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of infarct detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interrater variability of lesion detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative bioavailability of total curcuminoids (AUC0‐12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hip flexion strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: internal rotation strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: single-leg stance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remission of aggression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CD4 count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of sulphate metabolites of paracetamol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median freedom from progression
Endpoint domain: Mortality/survival
Primary endpoint: severity of trismus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OSA severity (apnea-hypopnea index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: subjective sleepiness (Epworth Sleepiness Scale)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Attendance at PST-SP sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Satisfaction with PST-SP
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Severity of anxiety symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of pain while awake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of functional impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: EFS (Event-Free Survival)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress urinary incontinence prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pelvic floor contraction strength assessment agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin concentration decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sustained virological response (SVR) 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implementation of urinalysis protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implementation of radiograph protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total effective rate of CM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of CI
Endpoint domain: Adverse events/effects
Primary endpoint: Serum levels of LDL-C, TC, and TG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of remaining gutta-percha/sealer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Death or development of LCOS requiring additional support
Endpoint domain: Mortality/survival
Primary endpoint: Decrease in visceral fat area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: nocturnal urine volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: NBCi
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perioperative complication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reflux scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: physical function scale score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: LVESV increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MR worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change in EQ-5D-VAS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Acceptance of the screening program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ongoing clinical pregnancy rate
Endpoint domain: Mortality/survival
Primary endpoint: Survival rate of vitrified oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Increase in clearance (CL) and clearance (CL(u)) after TBI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Health service costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Myocardial infarction during follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Intraoperative aspiration
Endpoint domain: Adverse events/effects
Primary endpoint: Total mean cost of procedure
Endpoint domain: Resource use
Primary endpoint: Improvement in repigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in facial rejuvenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Removal of b2MG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Levels of IS and pCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: incident PoAF lasting ≥ 30 seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total lumbar range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet glycoprotein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Recognition reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Subjective ratings of sedation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: all-cause mortality or HF hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Area under curve (AUC) for tumorigenesis prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under curve (AUC) for metastasis prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin test reactivity inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of barotitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ear outcomes
Primary endpoint: Reduction in calf swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in thigh swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CV death or HF hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients achieving improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IEMG of gastrocnemius muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change in depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage time spent above pH 4.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage time spent above pH 5.4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neuro-function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: cerebral blood circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of shocks per session
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Stone-free rates 3 months after ESWL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: VO2 max increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of physical activity at high intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in mental health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ejaculatory control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to delay ejaculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight gain offset
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 30-day major adverse cardiac events (MACE)
Endpoint domain: Mortality/survival
Primary endpoint: Bowel movement rate (BM/week)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serum HGF level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subdural pressure (SDP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral perfusion pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tactical driving performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VMHC in primary visual, somatosensory, and motor cortices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global VMHC correlation with average FA of the entire CC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes